Literature DB >> 23657749

Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors.

Christine S Landry1, Heather Y Lin, Alexandria Phan, Chusilp Charnsangavej, Eddie K Abdalla, Thomas Aloia, J Nicolas Vauthey, Matthew H G Katz, James C Yao, Jason B Fleming.   

Abstract

BACKGROUND: Neuroendocrine tumors of the small intestine commonly metastasize to regional lymph nodes (LNs). Single-institution reports suggest that removal of LNs improves outcome, but comprehensive data are lacking. We hypothesized that the extent of lymphadenectomy reported in a large administrative database would be associated with overall survival for jejunal and ileal neuroendocrine tumors.
METHODS: A search of the Surveillance Epidemiology and End Results database was performed for patients with jejunal and ileal neuroendocrine tumors from 1977 to 2004. Descriptive patient characteristics were collected to include age at diagnosis, sex, race, grade, primary tumor size, LN status, number of LNs resected, presence of distant metastasis, and the type of operation. Statistical analyses were limited to patients with only one primary tumor to exclude patients with other malignancies. Univariate and multivariate analyses were performed to analyze the number of LNs resected and the LN ratio (number of positive LNs/total number of LNs removed) to determine the effect on cancer-specific survival.
RESULTS: Altogether, 1,364 patients were included in this analysis. Removal of any LNs was associated with improved cancer-specific survival when compared to patients with no LN removal reported (p = 0.0027) on univariate analysis. Among those who had any LNs removed, a median of eight LNs were identified in resection specimens with a median LN ratio of 0.29 (range 0-1). On multivariate analysis (adjusting for age and tumor size), patients with >7 LNs removed experienced better cancer-specific survival than those with ≤ 7 LNs removed (median survival not reached vs. 140 months): hazard ratio and 95 % confidence interval were 0.573 (0.402, 0.817) (p = 0.002).
CONCLUSIONS: This review of a large number of surgical patients demonstrates that regional mesenteric lymphadenectomy in conjunction with resection of the primary tumor is associated with improved survival of patients with small bowel neuroendocrine tumors.

Entities:  

Mesh:

Year:  2013        PMID: 23657749      PMCID: PMC3881007          DOI: 10.1007/s00268-013-1918-8

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  9 in total

Review 1.  Midgut carcinoid tumours: surgical treatment and prognosis.

Authors:  Göran Kerström; Per Hellman; Ola Hessman
Journal:  Best Pract Res Clin Gastroenterol       Date:  2005-10       Impact factor: 3.043

2.  Management of carcinoid tumors.

Authors:  R G Martin
Journal:  Cancer       Date:  1970-09       Impact factor: 6.860

3.  Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.

Authors:  Marianne E Pavel; John D Hainsworth; Eric Baudin; Marc Peeters; Dieter Hörsch; Robert E Winkler; Judith Klimovsky; David Lebwohl; Valentine Jehl; Edward M Wolin; Kjell Öberg; Eric Van Cutsem; James C Yao
Journal:  Lancet       Date:  2011-11-25       Impact factor: 79.321

4.  Survival and prognostic factors in patients with small bowel carcinoid tumour.

Authors:  K Landerholm; N Zar; R E Andersson; S E Falkmer; J Järhult
Journal:  Br J Surg       Date:  2011-08-19       Impact factor: 6.939

5.  Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases.

Authors:  Per Hellman; Tobias Lundström; Ulf Ohrvall; Barbro Eriksson; Britt Skogseid; Kjell Oberg; Eva Tiensuu Janson; Göran Akerström
Journal:  World J Surg       Date:  2002-05-21       Impact factor: 3.352

Review 6.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

7.  Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years.

Authors:  Karl Y Bilimoria; David J Bentrem; Jeffrey D Wayne; Clifford Y Ko; Charles L Bennett; Mark S Talamonti
Journal:  Ann Surg       Date:  2009-01       Impact factor: 12.969

8.  Carcinoid tumors of the gastrointestinal tract.

Authors:  J G Morgan; C Marks; D Hearn
Journal:  Ann Surg       Date:  1974-11       Impact factor: 12.969

9.  Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

Authors:  James C Yao; Alexandria T Phan; David Z Chang; Robert A Wolff; Kenneth Hess; Sanjay Gupta; Carmen Jacobs; Jeannette E Mares; Andrea N Landgraf; Asif Rashid; Funda Meric-Bernstam
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

  9 in total
  23 in total

1.  Prognostic Factors in Curative Resected Locoregional Small Intestine Neuroendocrine Neoplasms.

Authors:  Maximilian Evers; Anja Rinke; Johannes Rütz; Annette Ramaswamy; Elisabeth Maurer; Detlef K Bartsch
Journal:  World J Surg       Date:  2021-01-08       Impact factor: 3.352

2.  Is Laparoscopic CME Right Hemicolectomy an Optimal Indication for NET of the Right Colon and Terminal Ileum?

Authors:  C Pedrazzani; C Conti; A Valdegamberi; M V Davì; S Cingarlini; A Scarpa; A Guglielmi
Journal:  J Gastrointest Surg       Date:  2020-08-03       Impact factor: 3.452

3.  Optimal Lymphadenectomy in Small Bowel Neuroendocrine Tumors: Analysis of the NCDB.

Authors:  Benjamin M Motz; Patrick D Lorimer; Danielle Boselli; Joshua S Hill; Jonathan C Salo
Journal:  J Gastrointest Surg       Date:  2017-08-17       Impact factor: 3.452

Review 4.  [Surgical aspects of neuroendocrine tumors of the small intestine].

Authors:  F Weber; H Dralle
Journal:  Chirurg       Date:  2018-06       Impact factor: 0.955

5.  Multifocal Small Bowel Neuroendocrine Tumours.

Authors:  Janice L Pasieka
Journal:  World J Surg       Date:  2021-01       Impact factor: 3.352

Review 6.  The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.

Authors:  James R Howe; Kenneth Cardona; Douglas L Fraker; Electron Kebebew; Brian R Untch; Yi-Zarn Wang; Calvin H Law; Eric H Liu; Michelle K Kim; Yusuf Menda; Brian G Morse; Emily K Bergsland; Jonathan R Strosberg; Eric K Nakakura; Rodney F Pommier
Journal:  Pancreas       Date:  2017-07       Impact factor: 3.327

7.  Lymphatic vessels regulate immune microenvironments in human and murine melanoma.

Authors:  Amanda W Lund; Marek Wagner; Manuel Fankhauser; Eli S Steinskog; Maria A Broggi; Stefani Spranger; Thomas F Gajewski; Kari Alitalo; Hans P Eikesdal; Helge Wiig; Melody A Swartz
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

Review 8.  Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract.

Authors:  Peter E Goretzki; Martina T Mogl; Aycan Akca; Johann Pratschke
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

9.  Surgical Management of Primary Small Bowel NET Presenting Acutely with Obstruction or Perforation.

Authors:  N S Rajaretnam; G Y Meyer-Rochow
Journal:  World J Surg       Date:  2020-07-21       Impact factor: 3.352

10.  Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors.

Authors:  Mohammad Y Zaidi; Alexandra G Lopez-Aguiar; Mary Dillhoff; Eliza Beal; George Poultsides; Eleftherios Makris; Flavio Rocha; Angelena Crown; Kamran Idrees; Paula Marincola Smith; Hari Nathan; Megan Beems; Daniel Abbott; James R Barrett; Ryan C Fields; Jesse Davidson; Kenneth Cardona; Shishir K Maithel
Journal:  JAMA Surg       Date:  2019-02-01       Impact factor: 14.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.